Detalles de la búsqueda
1.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Ann Hematol
; 98(2): 321-330, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446802
2.
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Haematologica
; 102(1): 103-109, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27686377
3.
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Blood
; 123(4): 494-500, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24311723
4.
Highly variable mutational profile of ASXL1 in myelofibrosis.
Eur J Haematol
; 97(4): 331-5, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26714837
5.
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Am J Hematol
; 90(5): 429-33, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25683327
6.
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Blood
; 119(22): 5221-8, 2012 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-22496165
7.
Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.
Am J Hematol
; 94(10): E264-E267, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31321810
8.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
N Engl J Med
; 362(24): 2260-70, 2010 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-20525995
9.
Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations.
J Clin Med
; 12(19)2023 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37835000
10.
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Cancers (Basel)
; 15(4)2023 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36831388
11.
Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients.
J Clin Med
; 11(20)2022 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36294538
12.
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.
Hemasphere
; 5(12): e657, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34853825
13.
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
J Clin Med
; 10(14)2021 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34300312
14.
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.
Cancer Rep (Hoboken)
; 4(4): e1358, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33656801
15.
Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
J Geriatr Oncol
; 11(1): 24-30, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30954406
16.
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Haematologica
; 99(4): e55-7, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24488561
17.
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Blood Cancer J
; 8(10): 91, 2018 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30504932
18.
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
J Clin Oncol
; 34(20): 2333-40, 2016 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27217448
19.
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Blood Cancer J
; 11(2): 16, 2021 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33563899
20.
Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.
J Clin Oncol
; 21(8): 1472-9, 2003 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12697869